MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome
Acute coronary syndrome (ACS) describes any condition characterized by myocardial ischaemia and reduction in blood flow. The physiopathological process of ACS is the atherosclerosis where MIF operates as a major regulator of inflammation. The aim of this study was to assess the mRNA expression of MI...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/9635652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225295101001728 |
|---|---|
| author | Emmanuel Valdés-Alvarado Yeminia Valle José Francisco Muñoz-Valle Ilian Janet García-Gonzalez Angelica Valdez-Haro Hector Enrique Flores-Salinas Jorge Manuel Pérez-Ibarra Elena Sandoval-Pinto Jorge Ramón Padilla-Gutiérrez |
| author_facet | Emmanuel Valdés-Alvarado Yeminia Valle José Francisco Muñoz-Valle Ilian Janet García-Gonzalez Angelica Valdez-Haro Hector Enrique Flores-Salinas Jorge Manuel Pérez-Ibarra Elena Sandoval-Pinto Jorge Ramón Padilla-Gutiérrez |
| author_sort | Emmanuel Valdés-Alvarado |
| collection | DOAJ |
| description | Acute coronary syndrome (ACS) describes any condition characterized by myocardial ischaemia and reduction in blood flow. The physiopathological process of ACS is the atherosclerosis where MIF operates as a major regulator of inflammation. The aim of this study was to assess the mRNA expression of MIF gene and its serum levels in the clinical manifestations of ACS and unrelated individuals age- and sex-matched with patients as the control group (CG). All samples were run using the conditions indicated in TaqMan Gene Expression Assay protocol. Determination of MIF serum levels were performed by enzyme-linked immunosorbent assay and MIF ELISA Kit. ST-segment elevation myocardial infraction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) showed 0.8 and 0.88, respectively, less expression of MIF mRNA with regard to CG. UA and STEMI presented more expression than NSTEMI 5.23 and 0.68, respectively. Otherwise, ACS patients showed significant higher MIF serum levels (p=0.02) compared with CG. Furthermore, the highest soluble levels of MIF were presented by STEMI (11.21 ng/dL), followed by UA (10.34 ng/dL) and finally NSTEMI patients (8.75 ng/dL); however, the differences were not significant. These novel observations further establish the process of MIF release after cardiovascular events and could support the idea of MIF as a new cardiac biomarker in ACS. |
| format | Article |
| id | doaj-art-52168669c6e64ee7944dcc87b4e60188 |
| institution | OA Journals |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-52168669c6e64ee7944dcc87b4e601882025-08-20T02:05:24ZengWileyCardiology Research and Practice2090-80162090-05972018-01-01201810.1155/2018/96356529635652MIF mRNA Expression and Soluble Levels in Acute Coronary SyndromeEmmanuel Valdés-Alvarado0Yeminia Valle1José Francisco Muñoz-Valle2Ilian Janet García-Gonzalez3Angelica Valdez-Haro4Hector Enrique Flores-Salinas5Jorge Manuel Pérez-Ibarra6Elena Sandoval-Pinto7Jorge Ramón Padilla-Gutiérrez8Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoCentro Médico Nacional de Occidente (CMNO), IMSS, Independencia Oriente, 44340 Guadalajara, JAL, MexicoEspecialidad de Cardiología, Centro Médico Nacional de Occidente (CMNO), IMSS, Independencia Oriente, 44340 Guadalajara, JAL, MexicoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, 44340 Guadalajara, JAL, MexicoAcute coronary syndrome (ACS) describes any condition characterized by myocardial ischaemia and reduction in blood flow. The physiopathological process of ACS is the atherosclerosis where MIF operates as a major regulator of inflammation. The aim of this study was to assess the mRNA expression of MIF gene and its serum levels in the clinical manifestations of ACS and unrelated individuals age- and sex-matched with patients as the control group (CG). All samples were run using the conditions indicated in TaqMan Gene Expression Assay protocol. Determination of MIF serum levels were performed by enzyme-linked immunosorbent assay and MIF ELISA Kit. ST-segment elevation myocardial infraction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) showed 0.8 and 0.88, respectively, less expression of MIF mRNA with regard to CG. UA and STEMI presented more expression than NSTEMI 5.23 and 0.68, respectively. Otherwise, ACS patients showed significant higher MIF serum levels (p=0.02) compared with CG. Furthermore, the highest soluble levels of MIF were presented by STEMI (11.21 ng/dL), followed by UA (10.34 ng/dL) and finally NSTEMI patients (8.75 ng/dL); however, the differences were not significant. These novel observations further establish the process of MIF release after cardiovascular events and could support the idea of MIF as a new cardiac biomarker in ACS.http://dx.doi.org/10.1155/2018/9635652 |
| spellingShingle | Emmanuel Valdés-Alvarado Yeminia Valle José Francisco Muñoz-Valle Ilian Janet García-Gonzalez Angelica Valdez-Haro Hector Enrique Flores-Salinas Jorge Manuel Pérez-Ibarra Elena Sandoval-Pinto Jorge Ramón Padilla-Gutiérrez MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome Cardiology Research and Practice |
| title | MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome |
| title_full | MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome |
| title_fullStr | MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome |
| title_full_unstemmed | MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome |
| title_short | MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome |
| title_sort | mif mrna expression and soluble levels in acute coronary syndrome |
| url | http://dx.doi.org/10.1155/2018/9635652 |
| work_keys_str_mv | AT emmanuelvaldesalvarado mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT yeminiavalle mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT josefranciscomunozvalle mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT ilianjanetgarciagonzalez mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT angelicavaldezharo mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT hectorenriquefloressalinas mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT jorgemanuelperezibarra mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT elenasandovalpinto mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome AT jorgeramonpadillagutierrez mifmrnaexpressionandsolublelevelsinacutecoronarysyndrome |